SEC Filing Summary: AspenBio Pharma, Inc. (Form 8-K)
Business Context and Reporting Period
This Form 8-K was filed by AspenBio Pharma, Inc. on March 18, 2009, reporting events that occurred on March 12, 2009. The registrant is a Colorado-based company focused on medical diagnostics, specifically the AppyScore® product line. Note: The request metadata referenced "Riot Platforms, Inc." and a 2009 date, but the provided filing text explicitly identifies the registrant as AspenBio Pharma, Inc.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on regulatory and operational milestones rather than financial performance.
Material Changes and Events
- FDA 510(k) Application: On March 12, 2009, the company announced it would proceed with filing a 510(k) application with the U.S. Food and Drug Administration (FDA) for its AppyScore® product.
- Investor Communication: The company held an "Investor Call Update" conference call on March 12, 2009, to discuss the regulatory progress and company status.
Guidance, Outlook, and Risks
The filing indicates a positive operational outlook regarding the regulatory pathway for AppyScore®. However, the text does not contain specific forward-looking financial guidance, detailed risk factors, or management commentary beyond the announcement of the FDA application and the conference call. The success of the 510(k) application remains a contingency for future commercialization.
Key Facts for Investor Verification
- Verify the status and expected timeline of the FDA 510(k) application for AppyScore®.
- Review the attached Exhibit 99.2 (Conference Call Transcript) for detailed management commentary on the regulatory strategy.
- Confirm the company's current cash position and runway, as this filing does not disclose liquidity details.
- Check for subsequent filings regarding the FDA's acceptance or decision on the 510(k) application.